AVN 944

Drug Profile

AVN 944

Alternative Names: AVN944; VX 944

Latest Information Update: 18 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Avalon Pharmaceuticals; Clinical Data; Vertex Pharmaceuticals
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Haematological malignancies; Pancreatic cancer

Most Recent Events

  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 11 Mar 2010 Discontinued - Phase-I for Haematological malignancies in USA (PO)
  • 29 May 2009 Avalon Pharmaceuticals has been acquired and merged into Clinical Data
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top